Literature DB >> 23551434

Epithelial-mesenchymal transition and clinicopathological correlation in craniopharyngioma.

Song-Tao Qi1, Jie Zhou, Jun Pan, Chao Zhang, Chotai Silky, Xiao-Rong Yan.   

Abstract

AIMS: To assess the immunophenotypic changes associated with epithelial-mesenchymal transition (EMT) in craniopharyngioma, especially at the tumour invasive front, and to correlate the findings with clinicopathological features and patient outcomes. METHODS AND
RESULTS: Forty-two craniopharyngiomas were investigated for the presence of EMT markers (vimentin, E-cadherin and β-catenin) by immunohistochemistry and western blot. The relationships between expression of these markers and various clinicopathological indicators and clinical outcomes of the tumours were analysed. There were statistically significant differences in the expression of vimentin and E-cadherin-β-catenin between adamantinomatous and papillary variants. The expression of vimentin and E-cadherin (but not that of β-catenin) in whole tumour sections was associated with tumour recurrence, and with postoperative weight and hypothalamic disturbances; the expression of vimentin and E-cadherin-β-catenin at the tumour invasive front was also associated with tumour recurrence, postoperative weight, and hypothalamic disturbances. The results from western blotting closely matched those of immunohistochemistry.
CONCLUSION: Our study demonstrates, for the first time, the potential prognostic implications of vimentin, E-cadherin and β-catenin expression in craniopharyngiomas. EMT may represent a crucial mechanism in the progression of craniopharyngiomas.
© 2012 Blackwell Publishing Ltd.

Entities:  

Keywords:  E-cadherin; craniopharyngioma; epithelial-mesenchymal transition; vimentin; β-catenin

Mesh:

Substances:

Year:  2012        PMID: 23551434     DOI: 10.1111/j.1365-2559.2012.04297.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

1.  Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.

Authors:  Jie Zhou; Chao Zhang; Jun Pan; Ligang Chen; Song-Tao Qi
Journal:  Mol Med Rep       Date:  2017-05-02       Impact factor: 2.952

2.  TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.

Authors:  Yi Liu; Chao-Hu Wang; Dan-Ling Li; Shi-Chao Zhang; Yu-Ping Peng; Jun-Xiang Peng; Ye Song; Song-Tao Qi; Jun Pan
Journal:  Oncotarget       Date:  2016-08-02

3.  Transcriptional co-expression regulatory network analysis for Snail and Slug identifies IL1R1, an inflammatory cytokine receptor, to be preferentially expressed in ST-EPN-RELA and PF-EPN-A molecular subgroups of intracranial ependymomas.

Authors:  Prit Benny Malgulwar; Vikas Sharma; Ashutosh Singh Tomar; Chaitenya Verma; Aruna Nambirajan; Manmohan Singh; Vaishali Suri; Chitra Sarkar; Mehar Chand Sharma
Journal:  Oncotarget       Date:  2018-10-26

4.  Matrix metalloproteinase 2 contributes to aggressive phenotype, epithelial-mesenchymal transition and poor outcome in nasopharyngeal carcinoma.

Authors:  Siyi Li; Weiren Luo
Journal:  Onco Targets Ther       Date:  2019-07-17       Impact factor: 4.147

5.  Identification and Characterization of TF-lncRNA Regulatory Networks Involved in the Tumorigenesis and Development of Adamantinomatous Craniopharyngioma.

Authors:  Dingkang Xu; Yufeng Guo; Shixiong Lei; Abao Guo; Dengpan Song; Qiang Gao; Shengqi Zhao; Kaiwen Yin; Qingjie Wei; Longxiao Zhang; Xiaoxuan Wang; Jie Wang; Qi Zhang; Fuyou Guo
Journal:  Front Oncol       Date:  2022-01-26       Impact factor: 6.244

6.  LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway.

Authors:  Shi-Peng Li; Hai-Xu Xu; Yao Yu; Jin-Dan He; Zhen Wang; Yan-Jie Xu; Chang-Ying Wang; Hai-Ming Zhang; Rong-Xin Zhang; Jian-Jun Zhang; Zhi Yao; Zhong-Yang Shen
Journal:  Oncotarget       Date:  2016-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.